HTL Biotechnology Completes Registration for “Sodium DNA Raw Material Main Document” (Polynucleotides) as a Medical Device, Leading the Chinese Market with Pharmaceutical-Grade Biopolymer Technology and Services
Recently, HTL Biotechnology completed the registration of the “Sodium DNA Raw Material Main Document” (Polynucleotides) as a medical device (number M2024199-000) in China.
This marks an important milestone for the company in advancing within the Chinese medical device market and pursuing global medical innovation. This achievement, following HTL Biotechnology’s acquisition of a recombinant protein platform (including rhCOL3) further establishes HTL Biotechnology as a global player in the pharmaceutical and biopolymer fields.
Polynucleotides as unique biopolymers, exhibit vast potential in fields such as medical aesthetics, wound repair, and tissue regeneration, owing to its unique repair and regeneration capabilities. Used in injectable medical devices, polynucleotides have regenerative anti-ageing and anti-inflammatory properties. They can also be added to cosmetic formulations to create regenerative cosmetic products.
As a major global supplier of low and high molecular weight polynucleotides, HTL Biotechnology has unique advantages in producing polynucleotide raw materials: HTL Biotechnology’s polynucleotides are produced from deep-sea wild salmon milt, which is reused as a co-product of sustainably fished wild salmon. Its manufacturing process preserves the original DNA structure with a extremely high level of purity and enables a wide range of molecular weights.
HTL Biotechnology operates two state-of-the-art production units for polynucleotides in France, efficiently meeting all customer demands and ensuring an uninterrupted supply chain. Additionally, the company is developing a new production area to further enhance productivity and accommodate the growing market needs.
To see our most recent news,
![](https://htlbiotech.com/wp-content/uploads/2023/08/partner-1.jpg)
Read more
news from us
-
Articles June 21, 2024
HTL Biotechnology at CPHI China 2024
CPHI China is one of Asia’s leading Pharma events for trading and networking with 3,500+ exhibitors and 90,000+ professionals from the pharmaceutical industry,
-
Articles June 13, 2024
Discover our Quality Policy
At HTL Biotechnology, we believe in going beyond together to achieve the highest quality standards.
-
Articles June 5, 2024
National Bioproduction and Biomedicine Day (TVR report)
On the occasion of the first National Bioproduction and Biomedicine Day, which took place on the last 5th july, we were very proud to welcome a TVR journalist in our Javené site for an exclusive report.